Nektar reports Q4 2022 net loss $59.7M; cash $505M, runway through mid-2025

NEKTAR THERAPEUTICS

2022-FY EPS reported -$1.97 revenue$92,055,000

Q4 2022 revenue $22.0M (down from $25.0M YoY); full-year revenue $92.1M (down from $101.9M).
Q4 net loss $59.7M ($0.32 loss per share) vs $145.6M ($0.79) in Q4 2021; full-year net loss $368.2M ($1.97) vs $523.8M ($2.86).
Cash and investments $505.0M at Dec 31, 2022, down from $798.8M; CEO expects runway through at least mid-2025 with additional cost cuts.
R&D expense fell to $34.7M in Q4 (from $99.6M) due to wind down of bempegaldesleukin program; restructuring costs $11.6M in Q4.
On Feb 23, 2023, announced Phase 2 topline data for rezpegaldesleukin in SLE; no Q4 earnings call held.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

NEKTAR THERAPEUTICS reported the quarter and year ended December 31, 2022 results: revenue Revenue in the fourth quarter of 2022 was $22.0 million, net income Net loss for the fourth quarter of 2022 was $59.7 million, EPS $0.32 basic and diluted loss per share.

Period: the quarter and year ended December 31, 2022
Revenue: Revenue in the fourth quarter of 2022 was $22.0 million
Net income: Net loss for the fourth quarter of 2022 was $59.7 million
EPS: $0.32 basic and diluted loss per share
Result: reported results

Exact text from the filing

On February 28, 2023, Nektar Therapeutics, a Delaware corporation (“Nektar”), issued a press release (the “Press Release”) announcing its financial results for the quarter and year ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

NEKTAR THERAPEUTICS filing history →

Source: SEC EDGAR

accession 0001213900-23-015546

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.